Home
/
VERTEX PHARMACEUTICALS INC / MA
/
Financials
/
Quarterly
VERTEX PHARMACEUTICALS INC / MA — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that VERTEX PHARMACEUTICALS INC / MA filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$640.80M
Apr 27, 2018
Q3
2017
Sep 30, 2017
$578.17M
Oct 30, 2017
Q2
2017
Jun 30, 2017
$544.14M
Jul 28, 2017
Q1
2018
Mar 31, 2017
$714.72M
Apr 27, 2018
Q3
2017
Sep 30, 2016
$413.78M
Oct 30, 2017
Q2
2017
Jun 30, 2016
$431.61M
Jul 28, 2017
Q1
2017
Mar 31, 2016
$398.08M
Apr 28, 2017
Q3
2016
Sep 30, 2015
$309.82M
Oct 31, 2016
Q2
2016
Jun 30, 2015
$166.08M
Aug 1, 2016
Q1
2016
Mar 31, 2015
$138.51M
May 3, 2016
Q3
2015
Sep 30, 2014
$178.99M
Oct 30, 2015
Q2
2015
Jun 30, 2014
$138.42M
Aug 4, 2015
Q1
2015
Mar 31, 2014
$118.45M
May 4, 2015
Q3
2014
Sep 30, 2013
$221.70M
Nov 6, 2014
Q2
2014
Jun 30, 2013
$310.75M
Jul 31, 2014
Q1
2014
Mar 31, 2013
$328.37M
May 5, 2014
Q3
2013
Sep 30, 2012
$336.01M
Nov 7, 2013
Q2
2013
Jun 30, 2012
$418.31M
Aug 2, 2013
Q1
2013
Mar 31, 2012
$438.74M
May 8, 2013
Q3
2012
Sep 30, 2011
$659.20M
Nov 6, 2012
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$3.08B
Nov 4, 2025
Q2
2025
Jun 30, 2025
$2.96B
Aug 5, 2025
Q1
2025
Mar 31, 2025
$2.77B
May 6, 2025
Q3
2025
Sep 30, 2024
$2.77B
Nov 4, 2025
Q2
2025
Jun 30, 2024
$2.65B
Aug 5, 2025
Q1
2025
Mar 31, 2024
$2.69B
May 6, 2025
Q3
2024
Sep 30, 2023
$2.48B
Nov 5, 2024
Q2
2024
Jun 30, 2023
$2.49B
Aug 2, 2024
Q1
2024
Mar 31, 2023
$2.37B
May 7, 2024
Q3
2023
Sep 30, 2022
$2.33B
Nov 7, 2023
Q2
2023
Jun 30, 2022
$2.20B
Aug 2, 2023
Q1
2023
Mar 31, 2022
$2.10B
May 2, 2023
Q3
2022
Sep 30, 2021
$1.98B
Oct 28, 2022
Q2
2022
Jun 30, 2021
$1.79B
Aug 5, 2022
Q1
2022
Mar 31, 2021
$1.72B
May 6, 2022
Q3
2021
Sep 30, 2020
$1.54B
Nov 3, 2021
Q2
2021
Jun 30, 2020
$1.52B
Jul 30, 2021
Q1
2021
Mar 31, 2020
$1.52B
Apr 30, 2021
Q3
2020
Sep 30, 2019
$949.83M
Oct 30, 2020
Q2
2020
Jun 30, 2019
$941.29M
Jul 31, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$1.08B
Nov 4, 2025
Q2
2025
Jun 30, 2025
$1.03B
Aug 5, 2025
Q1
2025
Mar 31, 2025
$646.30M
May 6, 2025
Q3
2025
Sep 30, 2024
$1.05B
Nov 4, 2025
Q2
2025
Jun 30, 2024
($3.59B)
Aug 5, 2025
Q1
2025
Mar 31, 2024
$1.10B
May 6, 2025
Q3
2024
Sep 30, 2023
$1.04B
Nov 5, 2024
Q2
2024
Jun 30, 2023
$915.70M
Aug 2, 2024
Q1
2024
Mar 31, 2023
$699.80M
May 7, 2024
Q3
2023
Sep 30, 2022
$930.50M
Nov 7, 2023
Q2
2023
Jun 30, 2022
$810.50M
Aug 2, 2023
Q1
2023
Mar 31, 2022
$762.10M
May 2, 2023
Q3
2022
Sep 30, 2021
$851.90M
Oct 28, 2022
Q2
2022
Jun 30, 2021
$67.00M
Aug 5, 2022
Q1
2022
Mar 31, 2021
$653.10M
May 6, 2022
Q3
2021
Sep 30, 2020
$667.43M
Nov 3, 2021
Q2
2021
Jun 30, 2020
$837.27M
Jul 30, 2021
Q1
2021
Mar 31, 2020
$602.75M
Apr 30, 2021
Q3
2020
Sep 30, 2019
$57.52M
Oct 30, 2020
Q2
2020
Jun 30, 2019
$267.43M
Jul 31, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$1.19B
Nov 4, 2025
Q2
2025
Jun 30, 2025
$1.15B
Aug 5, 2025
Q1
2025
Mar 31, 2025
$630.10M
May 6, 2025
Q3
2025
Sep 30, 2024
$1.12B
Nov 4, 2025
Q2
2025
Jun 30, 2024
($3.51B)
Aug 5, 2025
Q1
2025
Mar 31, 2024
$1.14B
May 6, 2025
Q3
2024
Sep 30, 2023
$1.04B
Nov 5, 2024
Q2
2024
Jun 30, 2023
$1.03B
Aug 2, 2024
Q1
2024
Mar 31, 2023
$779.00M
May 7, 2024
Q3
2023
Sep 30, 2022
$1.13B
Nov 7, 2023
Q2
2023
Jun 30, 2022
$1.11B
Aug 2, 2023
Q1
2023
Mar 31, 2022
$1.04B
May 2, 2023
Q3
2022
Sep 30, 2021
$1.05B
Oct 28, 2022
Q2
2022
Jun 30, 2021
($37.90M)
Aug 5, 2022
Q1
2022
Mar 31, 2021
$887.80M
May 6, 2022
Q3
2021
Sep 30, 2020
$672.24M
Nov 3, 2021
Q2
2021
Jun 30, 2020
$718.03M
Jul 30, 2021
Q1
2021
Mar 31, 2020
$720.22M
Apr 30, 2021
Q3
2020
Sep 30, 2019
$99.33M
Oct 30, 2020
Q2
2020
Jun 30, 2019
$269.96M
Jul 31, 2020